Aspire BioPharma, Inc. (ASBP) — Tangible Net Worth Ratio
Aspire BioPharma, Inc. (ASBP) has a Tangible Net Worth Ratio of 100.0% as of March 2026. This metric is calculated by deducting intangible assets ($0.00) from net assets ($3.87 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Aspire BioPharma, Inc. net asset momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Aspire BioPharma, Inc. Tangible Net Worth Ratio (2022–2023)
This chart shows how Aspire BioPharma, Inc.'s Tangible Net Worth Ratio has changed across 2 annual periods from 2022 to 2023. As of March 2026, the ratio stands at 100.0%, reflecting net assets of $3.87 Million with intangible assets of $0.00 USD. For live market cap and overall valuation, see market cap of Aspire BioPharma, Inc..
Annual Tangible Net Worth Ratio for Aspire BioPharma, Inc. (2022–2023)
The table below presents the year-by-year Tangible Net Worth Ratio for Aspire BioPharma, Inc. from 2022 to 2023, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore reinvestment intensity of Aspire BioPharma, Inc. to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 100.0% | $19.58 Million | $0.00 | $19.98 Million | ▲ +0.0 pp |
| 2022 | 100.0% | $289.07 Million | $0.00 | $300.18 Million | — |